NCT06645236 DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit
| NCT ID | NCT06645236 |
| Status | Recruiting |
| Phase | — |
| Sponsor | QIAGEN Gaithersburg, Inc |
| Condition | Metastatic Colorectal Cancer (mCRC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2023-12-22 |
| Primary Completion | 2030-10-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
To utilize the therascreen KRAS RGQ PCR Kit, as a screening test in Amgen's Phase 3 Clinical Study Protocol 20210081, in order to identify patients with mCRC KRAS G12C mutation positive tumors to be enrolled in the drug clinical trial. Results of the Phase 3 Amgen Study 20210081 will serve as the basis for establishing the clinical performance of the therascreen® KRAS RGQ PCR Kit as a companion diagnostic (CDx) for the identification of patients with metastatic colorectal cancer, who may benefit from treatment with sotorasib.
Eligibility Criteria
Inclusion Criteria: * Subjects who consent to participate in the eligibility screen for Protocol 20210081 will have their tumor tissue tested for the presence of KRAS G12C mutation under the proposed performance study. Exclusion Criteria: * There is no separate inclusion and exclusion criteria for the performance study.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.